Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

Kiora Pharmaceuticals (KPRX) EBIT Margin (2016 - 2024)

Kiora Pharmaceuticals' EBIT Margin history spans 9 years, with the latest figure at 82.64% for Q1 2024.

  • For Q1 2024, EBIT Margin changed N/A year-over-year to 82.64%; the TTM value through Dec 2024 reached 28.19%, changed N/A, while the annual FY2024 figure was 28.19%, N/A changed from the prior year.
  • EBIT Margin reached 82.64% in Q1 2024 per KPRX's latest filing, down from 395201.17% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 395201.17% in Q3 2022 to a low of 9698.8% in Q4 2020.
  • Average EBIT Margin over 4 years is 161914.67%, with a median of 146436.77% recorded in 2021.
  • The largest YoY upside for EBIT Margin was 16388546bps in 2021 against a maximum downside of 16388546bps in 2021.
  • A 4-year view of EBIT Margin shows it stood at 9698.8% in 2020, then surged by 1690bps to 154186.67% in 2021, then skyrocketed by 156bps to 395201.17% in 2022, then tumbled by -100bps to 82.64% in 2024.
  • Per Business Quant, the three most recent readings for KPRX's EBIT Margin are 82.64% (Q1 2024), 395201.17% (Q3 2022), and 154186.67% (Q4 2021).